Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Activity
Last 14 days
Efficacy of Modified Release Metaxalone 640 mg in Acute Lumbosacral Musculoskeletal Conditions With Spinal Stenosis and Sciatica
Treatment of Digital Ulcers in Systemic Sclerosis With Diosmin: A Randomized, Double-blind, Placebo-controlled Multi-centre Pilot Study
Assessment of the Effect of Metaxalone 640 mg (M640) on Truck Driving Ability and Cognition Compared to Tizanidine 8 mg: A Prospective, Single-blind, Within-subject Pilot Study
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Diprolene — DIPROSONE
Application NDA017781 (NDA)
Diprolene — DIPROSONE
Application NDA017829 (NDA)
Diprolene — DIPROSONE
Application NDA017691 (NDA)
Diprolene — DIPROSONE
Application NDA017536 (NDA)
Diprolene — DIPROLENE
Application NDA018741 (NDA)
Diprolene — BETAMETHASONE DIPROPIONATE
Application NDA019141 (NDA)
Diprolene — ALPHATREX
Application NDA019143 (NDA)
Diprolene — BETAMETHASONE DIPROPIONATE
Application NDA019140 (NDA)
Diprolene — ALPHATREX
Application NDA019138 (NDA)
Diprolene — BETAMETHASONE DIPROPIONATE
Application NDA019137 (NDA)
Diprolene — BETAMETHASONE DIPROPIONATE
Application NDA019136 (NDA)
Diprolene — DIPROLENE
Application NDA019408 (NDA)
Diprolene — DIPROLENE AF
Application NDA019555 (NDA)
Diprolene — DIPROLENE
Application NDA019716 (NDA)
Diprolene — SERNIVO
Application NDA208079 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)